Citations

Mayo Clinic

Showing 10 of 108599 citations.

Does the trait anxiety affect the dental fear?
Doğaner, Yusuf Çetin , Aydoğan, Ümit , YESIL, Hande Ucler , Rohrer, James E. , Williams, Mark Douglas, Agerter, David C., Agerter, David Charles

Brazilian Oral Research | May 5, 2017 | Volume: 31 | Pages: No page available

10.1590/1807-3107bor-2017.vol31.0036 | PMID 28513787 Get It

Editorial: risk factors for persistent villus atrophy in coeliac disease – is it time to reconsider definitions for refractory coeliac disease? Authors' reply
Mahadev, SriHari , Green, P. H. R., Adelman, Donna, Lebwohl, Benjamin , Mahadev, S , Murray, Joseph A.

Alimentary Pharmacology & Therapeutics | May 5, 2017 | Volume: 45 | Issue: 11 | Pages: 1478-1479

10.1111/apt.14086 | PMID 28474831 Get It

Linked ContentThis article is linked to Mahadev et al and Braude, Newnham papers. To view these articles visit https://doi.org/10.1111/apt.13988 and https://doi.org/10.1111/apt.14055.
Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis
Zeydan, Burcu , Lowe, Val J. , Przybelski, Scott A. , Tosakulwong, Nirubol , Zuk, Samantha M., Senjem, Matthew L. , Gunter, Jeffrey L. , Roberts, Rosebud O., Mielke, Michelle M. , Benarroch, Eduardo E. , Rodriguez, Moses , Lesnick, Timothy G. , Petersen, Ronald C. , Jack, Clifford R. , Kantarci, Kejal , Kantarci, Orhun H. , Schwarz, Christopher G. , Machulda, Mary M. , Knopman, David S. , Jack, Clifford R , Mielke, Michelle M , Senjem, Matthew L , Kantarci, Kejal , Rodriguez, Moses , Zeydan, Burcu

Multiple Sclerosis Journal | May 5, 2017 | Volume: 24 | Issue: 6 | Pages: 739-749

10.1177/1352458517707346 | PMID 28474977 Get It

Background: There is growing interest in white matter (WM) imaging with positron emission tomography (PET). Objectives: We studied the association of cognitive function in late multiple sclerosis (MS) with cortical and WM Pittsburgh compound-B PET (PiB-PET) binding. Methods: In the population-based Mayo Clinic Study of Aging, 24 of 4869 participants had MS (12 underwent PiB-PET). Controls were age and sex matched (5:1). We used automated or semi-automated processing for quantitative image analyses and conditional logistic regression for group differences. Results: MS patients had lower memory ( p = 0.03) and language ( p = 0.02) performance; smaller thalamic volumes ( p = 0.003); and thinner temporal ( p = 0.001) and frontal ( p = 0.045) cortices on magnetic resonance imaging (MRI) than controls. There was no difference in global cortical PiB standardized uptake value ratios between MS and controls ( p = 0.35). PiB uptake was lower in areas of WM hyperintensities compared to normal-appearing white matter (NAWM) in MS ( p = 0.0002). Reduced PiB uptake in both the areas of WM hyperintensities ( r = 0.65; p = 0.02) and NAWM ( r = 0.69; p = 0.01) was associated with decreased visuospatial performance in MS. Conclusion: PiB uptake in the cortex in late MS is not different from normal age-matched controls. PiB uptake in the WM in late MS may be a marker of the large network structures’ integrity such as those involved in visuospatial performance.
Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*
Nanah, Rama , McCullough, Kristen , Begna, Kebede H. , Patnaik, Mrinal M. , Elliott, Michelle A. , Litzow, Mark R. , Al‐Kali, Aref , Hogan, William, Patnaik, Mrinal , Hogan, William J. , McCullough, Kristen B

American Journal of Hematology | May 5, 2017 | Volume: 92 | Issue: 9 | Pages: 866-871

10.1002/ajh.24780 | PMID 28474744 Get It

Outcomes of acute myeloid leukemia (AML) in elderly patients unfit for intensive chemotherapy is challenging. Hypomethylating agents (HMAs) can be effective in these patients but responses are usually short‐lived. The majority of patients will either have stable disease or progress through therapy. We hereby describe the outcome of these patients at our institution after they fail HMAs. The data on 56 AML patients at Mayo Clinic, Rochester were reviewed. Patients were considered for our study if they received HMA as frontline therapy for their AML. Out of 56 patients, 15 (27%) patients received azacitidine (AZA) and 41 (73%) received decitabine. Complete remission was found in 10 (18%), with overall response of 28% and median response duration of 10 months. Thirteen (81%) out of 16 responders relapsed. Therefore 53 patients were included in the primary or secondary failure analysis with a median overall survival (OS) of 2 months after the date of failure. Out of 53 patients, 12 (23%) received subsequent treatments. None of the 12 patients who got first salvage therapy achieved remission. Five out of the 12 patients received second salvage therapy, 2 (40%) of which achieved CR. Median OS for patients who received subsequent salvage therapies was better than those who did not receive any subsequent therapy after failing HMA (9.5 vs. 2 months, P = .0009). Outcome for patients who have primary or secondary failure is very poor. Our study provides important historical data for future novel therapies, which are sorely needed for these patients.
Low rates of contralateral neck failure in unilaterally treated oropharyngeal squamous cell carcinoma with prospectively defined criteria of lateralization
Hu, Kenneth S. , Gamez, Mauricio E. , Safdieh, Joseph, Lin, Wilson, Jacobson, A. , Urken, Mark L. , Culliney, B., Li, Zujun, Tran, Theresa , Schantz, Stimson P., Chadha, Juskaran , Harrison, Louis B., Hu, Kenneth Shung , Gamez, Mauricio , Mourad, Waleed Fouad , Persky, Mark Stephen

Head & Neck | May 5, 2017 | Volume: 39 | Issue: 8 | Pages: 1647-1654

10.1002/hed.24806 | PMID 28474380 Get It

AbstractBackgroundUnilateral radiotherapy (RT) of oropharyngeal carcinomas is accepted for patients with lateralized primary and low‐volume nodal disease. Utilizing prospectively defined criteria of laterality and staging positron emission tomography (PET)/CT, we studied outcomes in patients with advanced‐stage oropharyngeal cancer undergoing unilateral RT.MethodsThirty‐seven patients with oropharyngeal tumors >1 cm from midline regardless of node status underwent unilateral RT and were followed prospectively. Patient characteristics: T1 = 11; T2 = 22; T3 = 4; N0 = 3; N1 = 9; N2a = 3; N2b = 21; and Nx = 1. Dosimetry were determined and weekly National Comprehensive Cancer Network (NCCN) distress thermometer data were collected.ResultsAt median follow‐up of 32 months, 3‐year locoregional control, contralateral regional failure, distant metastasis‐free survival, and disease‐free survival were 96%, 0%, 7%, and 93%, respectively.ConclusionLow rates of contralateral neck failure are demonstrated utilizing prospectively defined criteria for unilateral RT. The tolerances of contralateral organs are respected and patients report low to moderate levels of distress throughout treatment.
TNFα decreases mitochondrial movement in human airway smooth muscle
Delmotte, Philippe , Zavaletta, Vanessa A., Prakash, Y. S. , Sieck, Gary C. , Prakash, Y S , Thompson, Michael A. , Sieck, Gary

American Journal of Physiology-Lung Cellular and Molecular Physiology | May 5, 2017 | Volume: 313 | Issue: 1 | Pages: L166-L176

10.1152/ajplung.00538.2016 | PMID 28473328 Get It

In airway smooth muscle (ASM) cells, excitation-contraction coupling is accomplished via a cascade of events that connect an elevation of cytosolic Ca2+concentration ([Ca2+]cyt) with cross-bridge attachment and ATP-consuming mechanical work. Excitation-energy coupling is mediated by linkage of the elevation of [Ca2+]cytto an increase in mitochondrial Ca2+concentration, which in turn stimulates ATP production. Proximity of mitochondria to the sarcoplasmic reticulum (SR) and plasma membrane is thought to be an important mechanism to facilitate mitochondrial Ca2+uptake. In this regard, mitochondrial movement in ASM cells may be key in establishing proximity. Mitochondria also move where ATP or Ca2+buffering is needed. Mitochondrial movement is mediated through interactions with the Miro-Milton molecular complex, which couples mitochondria to kinesin motors at microtubules. We examined mitochondrial movement in human ASM cells and hypothesized that, at basal [Ca2+]cytlevels, mitochondrial movement is necessary to establish proximity of mitochondria to the SR and that, during the transient increase in [Ca2+]cytinduced by agonist stimulation, mitochondrial movement is reduced, thereby promoting transient mitochondrial Ca2+uptake. We further hypothesized that airway inflammation disrupts basal mitochondrial movement via a reduction in Miro and Milton expression, thereby disrupting the ability of mitochondria to establish proximity to the SR and, thus, reducing transient mitochondrial Ca2+uptake during agonist activation. The reduced proximity of mitochondria to the SR may affect establishment of transient “hot spots” of higher [Ca2+]cytat the sites of SR Ca2+release that are necessary for mitochondrial Ca2+uptake via the mitochondrial Ca2+uniporter.
Letter on “Natural history of pure autonomic failure: A United States prospective cohort”
Silber, Michael H. , Louis, Erik K. St. , St Louis, Erik K, Boeve, Bradley F. , St Louis, E K

Annals of Neurology | May 4, 2017 | Volume: 81 | Issue: 6 | Pages: 910-910

10.1002/ana.24948 | PMID 28472851 Get It

Finding the grave of Sir William Richard Gowers
Toodayan, Nadeem , Lees, Andrew, Boes, Christopher J.

Practical Neurology | May 4, 2017 | Volume: 17 | Issue: 4 | Pages: 321-322

10.1136/practneurol-2017-001648 | PMID 28473605 Get It

Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance
Ho, Yeung, Etten, Jamie L. Van, Yang, Rendong , Li, Yingming , Tseng, Elizabeth , Hon, Ting, Clark, Tyson A. , Tan, Winston , Carlson, Rachel E. , Wang, Liguo , Sicotte, Hugues , Ho, Thai H. , Jiménez, Rafael E. , Vedell, Peter T. , Eckloff, Bruce W., Quevedo, J. Fernando , Pitot, Henry C., Costello, Brian A. , Jen, Jin , Wieben, Eric D. , Silverstein, Kevin A.T. , Wang, Liewei , Dehm, Scott M. , Kohli, Manish , Thai, Ho, Jimenez, Rafael, Quevedo, Jorge F, Hillman, David W. , Henzler, Christine M. , Sperger, Jamie M. , Huang, Haojie , Lang, Joshua M. , Ho, Thai , Wang, Liguo , Dehm, Scott M

Clinical Cancer Research | May 4, 2017 | Volume: 23 | Issue: 16 | Pages: 4704-4715

10.1158/1078-0432.ccr-17-0017 | PMID 28473535 Get It

Abstract Purpose: Androgen receptor (AR) variant AR-V7 is a ligand-independent transcription factor that promotes prostate cancer resistance to AR-targeted therapies. Accordingly, efforts are under way to develop strategies for monitoring and inhibiting AR-V7 in castration-resistant prostate cancer (CRPC). The purpose of this study was to understand whether other AR variants may be coexpressed with AR-V7 and promote resistance to AR-targeted therapies. Experimental Design: We utilized complementary short- and long-read sequencing of intact AR mRNA isoforms to characterize AR expression in CRPC models. Coexpression of AR-V7 and AR-V9 mRNA in CRPC metastases and circulating tumor cells was assessed by RNA-seq and RT-PCR, respectively. Expression of AR-V9 protein in CRPC models was evaluated with polyclonal antisera. Multivariate analysis was performed to test whether AR variant mRNA expression in metastatic tissues was associated with a 12-week progression-free survival endpoint in a prospective clinical trial of 78 CRPC-stage patients initiating therapy with the androgen synthesis inhibitor, abiraterone acetate. Results: AR-V9 was frequently coexpressed with AR-V7. Both AR variant species were found to share a common 3′ terminal cryptic exon, which rendered AR-V9 susceptible to experimental manipulations that were previously thought to target AR-V7 uniquely. AR-V9 promoted ligand-independent growth of prostate cancer cells. High AR-V9 mRNA expression in CRPC metastases was predictive of primary resistance to abiraterone acetate (HR = 4.0; 95% confidence interval, 1.31–12.2; P = 0.02). Conclusions: AR-V9 may be an important component of therapeutic resistance in CRPC. Clin Cancer Res; 23(16); 4704–15. ©2017 AACR.